Myriad Genetics

MYGN

Market cap $584M

Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar.

New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.

Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026. “Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise,” said Sam Raha, Chief Executive Officer, Myriad Genetics.

MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.

Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.